Hydrogels to model 3D in vitro microenvironment of tumor vascularization

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 19-29

  Song, Hyun Ho Greco ^a   Park, Kyung Min ^a   Gerecht, Sharon ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Angiogenesis; ECM remodeling; Hydrogel; Three dimensional cell culture; Tumor modeling

Indexed keywords

3D PRINTERS; CELL CULTURE; HYDROGELS; TUMORS;

ANGIOGENESIS; ANGIOGENESIS PROCESS; DESIGN PARAMETERS; MICROFLUIDIC CHANNEL; THREE DIMENSIONAL CELL CULTURE; TUMOR ANGIOGENESIS; TUMOR MODELS; TUMOR VASCULARIZATION;

3D MODELING;

ANGIOGENESIS; BIOPRINTING; CANCER CELL; CANCER TISSUE; HUMAN; HYDROGEL; IN VITRO STUDY; MICROFLUIDICS; MICROVASCULATURE; MODEL; NONHUMAN; REVIEW; THREE DIMENSIONAL CULTURE MODEL; TISSUE ENGINEERING; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE TECHNIQUE; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROCEDURES; VASCULARIZATION;

HYDROGEL;

ANIMALS; CELL CULTURE TECHNIQUES; HUMANS; HYDROGELS; IN VITRO TECHNIQUES; MICROFLUIDICS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT;

EID: 84919952876     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.06.002     Document Type: Review

References (144)

1. Howlader N.A., Krapcho M., Garshell J., Neyman N., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., Cho H., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J. SEER Cancer Statistics Review, 1975-2010 2013, National Cancer Institute, Bethesda, MD, (pp. Based on November 2012 SEER data submission, posted to the SEER web site, April 2013). C. Ka (Ed.).
2. Cao Y., DePinho R.A., Ernst M., Vousden K. Cancer research: past, present and future. Nat. Rev. Cancer 2011, 11:749-754.
3. Carden C.P., Banerji U., Kaye S.B., Workman P., de Bono J.S. From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin. Pharmacol. Ther. 2009, 85:131-133.
4. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 2012, 64:353-365.
5. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., Mooney D.J. Engineering tumors with 3D scaffolds. Nat. Methods 2007, 4:855-860.
6. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
7. Wirtz D., Konstantopoulos K., Searson P.C. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat. Rev. Cancer 2011, 11:512-522.
8. Gordon M.S., Mendelson D.S., Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int. J. Cancer 2010, 126:1777-1787.
9. Infanger D.W., Pathi S.P., Fischbach C. Microenvironmental Regulation of Tumor Angiogenesis: Biological and Engineering Considerations 2011, 167-202.
10. Rivera L., Pandika M., Bergers G. Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. Tumor Microenvironment and Cellular Stress 2014, 83-99. Springer.
11. Smith N.R., Baker D., Farren M., Pommier A., Swann R., Wang X., Mistry S., McDaid K., Kendrew J., Womack C., Wedge S.R., Barry S.T. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin. Cancer Res. 2013, 19:6943-6956.
12. Claesson-Welsh L., Welsh M. VEGFA and tumour angiogenesis. J. Intern. Med. 2013, 273:114-127.
13. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
14. Kozin S.V., Duda D.G., Munn L.L., Jain R.K. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?. J. Natl. Cancer Inst. 2012, 104:899-905.
15. Lieu C.H., Tan A.C., Leong S., Diamond J.R., Eckhardt S.G. From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J. Natl. Cancer Inst. 2013, 105:1441-1456.
16. Beecken W.-D.C., Fernandez A., Joussen A.M., Achilles E.-G., Flynn E., Lo K.-M., Gillies S.D., Javaherian K., Folkman J., Shing Y. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J. Natl. Cancer Inst. 2001, 93:382-387.
17. Nelson N.J. Angiogenesis research is on fast forward. J. Natl. Cancer Inst. 1999, 91:820-822.
18. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 2002, 94:883-893.
19. Burdett E., Kasper F.K., Mikos A.G., Ludwig J.A. Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Eng. B Rev. 2010, 16:351-359.
20. Dickinson L.E., Lütgebaucks C., Lewis D.M., Gerecht S. Patterning microscale extracellular matrices to study endothelial and cancer cell interactions in vitro. Lab Chip 2012, 12:4244-4248.
21. Hanjaya-Putra D., Wong K.T., Hirotsu K., Khetan S., Burdick J.A., Gerecht S. Spatial control of cell-mediated degradation to regulate vasculogenesis and angiogenesis in hyaluronan hydrogels. Biomaterials 2012, 33:6123-6131.
22. Hielscher A.C., Gerecht S. Engineering approaches for investigating tumor angiogenesis: exploiting the role of the extracellular matrix. Cancer Res. 2012, 72:6089-6096.
23. Kusuma S., Zhao S., Gerecht S. The extracellular matrix is a novel attribute of endothelial progenitors and of hypoxic mature endothelial cells. FASEB J. 2012, 26:4925-4936.
24. Liang Y., Jeong J., DeVolder R.J., Cha C., Wang F., Tong Y.W., Kong H. A cell-instructive hydrogel to regulate malignancy of 3D tumor spheroids with matrix rigidity. Biomaterials 2011, 32:9308-9315.
25. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol. 2010, 28:125-133.
26. Decaup E., Jean C., Laurent C., Gravelle P., Fruchon S., Capilla F., Marrot A., Al Saati T., Frenois F., Laurent G. Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. Blood Cancer J. 2013, 3:e131.
27. Ghajar C.M., Bissell M.J. Tumor engineering: the other face of tissue engineering. Tissue Eng. A 2010, 16:2153-2156.
28. Loessner D., Rizzi S.C., Stok K.S., Fuehrmann T., Hollier B., Magdolen V., Hutmacher D.W., Clements J.A. A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread. Biomaterials 2013, 34:7389-7400.
29. Pickl M., Ries C. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2008, 28:461-468.
30. Szot C.S., Buchanan C.F., Freeman J.W., Rylander M.N. 3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials 2011, 32:7905-7912.
31. Håkanson M., Cukierman E., Charnley M. Miniaturized pre-clinical cancer models as research and diagnostic tools. Adv. Drug Deliv. Rev. 2014, 69-70:52-66.
32. Weigelt B., Ghajar C.M., Bissell M.J. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Advanced Drug Delivery Reviews 2014, 69-70:42-51.
33. Senger D.R., Davis G.E. Angiogenesis. Cold Spring Harb. Perspect. Biol. 2011, 3.
34. Seano G., Chiaverina G., Gagliardi P.A., di Blasio L., Sessa R., Bussolino F., Primo L. Modeling human tumor angiogenesis in a three-dimensional culture system. Blood 2013, 121:e129-e137.
35. Aubin H., Nichol J.W., Hutson C.B., Bae H., Sieminski A.L., Cropek D.M., Akhyari P., Khademhosseini A. Directed 3D cell alignment and elongation in microengineered hydrogels. Biomaterials 2010, 31:6941-6951.
36. Huang N.F., Lai E.S., Ribeiro A.J.S., Pan S., Pruitt B.L., Fuller G.G., Cooke J.P. Spatial patterning of endothelium modulates cell morphology, adhesiveness and transcriptional signature. Biomaterials 2013, 34:2928-2937.
37. Huang N.F., Okogbaa J., Lee J.C., Jha A., Zaitseva T.S., Paukshto M.V., Sun J.S., Punjya N., Fuller G.G., Cooke J.P. The modulation of endothelial cell morphology, function, and survival using anisotropic nanofibrillar collagen scaffolds. Biomaterials 2013, 34:4038-4047.
38. Smith Q., Gerecht S. Going with the flow: microfluidic platforms in vascular tissue engineering. Curr. Opin. Chem. Eng. 2014, 3:42-50.
39. Barreto-Ortiz S.F., Zhang S., Davenport M., Fradkin J., Ginn B., Mao H.-Q., Gerecht S. A novel in vitro model for microvasculature reveals regulation of circumferential ECM organization by curvature. PLoS ONE 2013, 8:e81061.
40. Bian L., Guvendiren M., Mauck R.L., Burdick J.A. Hydrogels that mimic developmentally relevant matrix and N-cadherin interactions enhance MSC chondrogenesis. Proc. Natl. Acad. Sci. 2013, 110:10117-10122.
41. Grayson W.L., Fröhlich M., Yeager K., Bhumiratana S., Chan M.E., Cannizzaro C., Wan L.Q., Liu X.S., Guo X.E., Vunjak-Novakovic G. Engineering anatomically shaped human bone grafts. Proc. Natl. Acad. Sci. 2010, 107:3299-3304.
42. Sun G., Zhang X., Shen Y.-I., Sebastian R., Dickinson L.E., Fox-Talbot K., Reinblatt M., Steenbergen C., Harmon J.W., Gerecht S. Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing. Proc. Natl. Acad. Sci. 2011, 108:20976-20981.
43. Drury J.L., Mooney D.J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 2003, 24:4337-4351.
44. Hoffman A.S. Hydrogels for biomedical applications. Adv. Drug Deliv. Rev. 2012, 64:18-23.
45. Peppas N.A., Hilt J.Z., Khademhosseini A., Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv. Mater. 2006, 18:1345-1360.
46. Burdick J.A., Prestwich G.D. Hyaluronic acid hydrogels for biomedical applications. Adv. Mater. 2011, 23:H41-H56.
47. Cuchiara M.P., Gould D.J., McHale M.K., Dickinson M.E., West J.L. Integration of self-assembled microvascular networks with microfabricated PEG-based hydrogels. Adv. Funct. Mater. 2012, 22:4511-4518.
48. Nguyen D.-H.T., Stapleton S.C., Yang M.T., Cha S.S., Choi C.K., Galie P.A., Chen C.S. Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro. Proc. Natl. Acad. Sci. 2013, 110:6712-6717.
49. Zheng Y., Chen J., Craven M., Choi N.W., Totorica S., Diaz-Santana A., Kermani P., Hempstead B., Fischbach-Teschl C., López J.A. In vitro microvessels for the study of angiogenesis and thrombosis. Proc. Natl. Acad. Sci. 2012, 109:9342-9347.
50. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
51. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
52. Raza A., Franklin M.J., Dudek A.Z. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am. J. Hematol. 2010, 85:593-598.
53. Yana I., Sagara H., Takaki S., Takatsu K., Nakamura K., Nakao K., Katsuki M., Taniguchi S.-i., Aoki T., Sato H. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J. Cell Sci. 2007, 120:1607-1614.
54. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
55. Hayashi M., Majumdar A., Li X., Adler J., Sun Z., Vertuani S., Hellberg C., Mellberg S., Koch S., Dimberg A. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat. Commun. 2013, 4:1672.
56. Schedin P., Keely P.J. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb. Perspect. Biol. 2011, 3.
57. Daenen L.G., Shaked Y., Man S., Xu P., Voest E.E., Hoffman R.M., Chaplin D.J., Kerbel R.S. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol. Cancer Ther. 2009, 8:2872-2881.
58. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18:3964-3972.
59. Butler J.M., Kobayashi H., Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 2010, 10:138-146.
60. Masuda H., Asahara T. Post-natal endothelial progenitor cells for neovascularization in tissue regeneration. Cardiovasc. Res. 2003, 58:390-398.
61. Liu A.Y., Ouyang G. Tumor angiogenesis: a new source of pericytes. Curr. Biol. 2013, 23:R565-R568.
62. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
63. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 2005, 23:47-55.
64. Place E.S., Evans N.D., Stevens M.M. Complexity in biomaterials for tissue engineering. Nat. Mater. 2009, 8:457-470.
65. Putnam A.J., Mooney D.J. Tissue engineering using synthetic extracellular matrices. Nat. Med. 1996, 2:824-826.
66. Cushing M.C., Anseth K.S. Hydrogel cell cultures. Science 2007, 316:1133-1134.
67. Gill B.J., Gibbons D.L., Roudsari L.C., Saik J.E., Rizvi Z.H., Roybal J.D., Kurie J.M., West J.L. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res. 2012, 72:6013-6023.
68. Ko D.Y., Shinde U.P., Yeon B., Jeong B. Recent progress of in situ formed gels for biomedical applications 2013, 38:672-701.
69. Chung H.J., Park T.G. Self-assembled and nanostructured hydrogels for drug delivery and tissue engineering 2009, 4:429-437.
70. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr. Opin. Cell Biol. 2004, 16:14-23.
71. Galbraith C.G., Sheetz M.P. Forces on adhesive contacts affect cell function. Curr. Opin. Cell Biol. 1998, 10:566-571.
72. Maheshwari G., Brown G., Lauffenburger D.A., Wells A., Griffith L.G. Cell adhesion and motility depend on nanoscale RGD clustering. J. Cell Sci. 2000, 113(Pt 10):1677-1686.
73. Geiger B., Bershadsky A., Pankov R., Yamada K.M. Transmembrane crosstalk between the extracellular matrix-cytoskeleton crosstalk. Nat. Rev. Mol. Cell Biol. 2001, 2:793-805.
74. Kleinman H.K., McGarvey M.L., Liotta L.A., Robey P.G., Tryggvason K., Martin G.R. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982, 21:6188-6193.
75. Benton G., Kleinman H.K., George J., Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int. J. Cancer 2011, 128:1751-1757.
76. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1:84-96.
77. Arnaoutova I., Kleinman H.K. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat. Protoc. 2010, 5:628-635.
78. Auerbach R., Lewis R., Shinners B., Kubai L., Akhtar N. Angiogenesis assays: a critical overview. Clin. Chem. 2003, 49:32-40.
79. O'Connell K.A., Edidin M. A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J. Immunol. 1990, 144:521-525.
80. Ades E.W., Candal F.J., Swerlick R.A., George V.G., Summers S., Bosse D.C., Lawley T.J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 1992, 99:683-690.
81. Khoo C.P., Micklem K., Watt S.M. A comparison of methods for quantifying angiogenesis in the Matrigel assay in vitro. Tissue Eng. Part C Methods 2011, 17:895-906.
82. Chevallay B., Herbage D. Collagen-based biomaterials as 3D scaffold for cell cultures: applications for tissue engineering and, gene therapy 2000, 38:211-218.
83. Gordon M.K., Hahn R.A. Collagens. Cell Tissue Res. 2010, 339:247-257.
84. Shoulders M.D., Raines R.T. Collagen structure and stability. Annu. Rev. Biochem. 2009, 78:929-958.
85. Ramachandran G.N. Structure of collagen. Nature 1956, 177:710-711.
86. Szot C.S., Buchanan C.F., Freeman J.W., Rylander M.N. In vitro angiogenesis induced by tumor-endothelial cell co-culture in bilayered, collagen I hydrogel bioengineered tumors. Tissue Eng. Part C Methods 2013, 19:864-874.
87. Mosesson M.W. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost. 2005, 3:1894-1904.
88. Liu J., Tan Y., Zhang H., Zhang Y., Xu P., Chen J., Poh Y.C., Tang K., Wang N., Huang B. Soft fibrin gels promote selection and growth of tumorigenic cells. Nat. Mater. 2012, 11:734-741.
89. Infanger D.W., Lynch M.E., Fischbach C. Engineered culture models for studies of tumor-microenvironment interactions. Annu. Rev. Biomed. Eng. 2013, 15:29-53.
90. Kosaki R., Watanabe K., Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res. 1999, 59:1141-1145.
91. Bharadwaj A.G., Kovar J.L., Loughman E., Elowsky C., Oakley G.G., Simpson M.A. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am. J. Pathol. 2009, 174:1027-1036.
92. Gurski L.A., Jha A.K., Zhang C., Jia X., Farach-Carson M.C. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 2009, 30:6076-6085.
93. Xu X., Gurski L.A., Zhang C., Harrington D.A., Farach-Carson M.C., Jia X. Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids. Biomaterials 2012, 33:9049-9060.
94. Hanjaya-Putra D., Bose V., Shen Y.I., Yee J., Khetan S., Fox-Talbot K., Steenbergen C., Burdick J.A., Gerecht S. Controlled activation of morphogenesis to generate a functional human microvasculature in a synthetic matrix. Blood 2011, 118:804-815.
95. Kusuma S., Shen Y.I., Hanjaya-Putra D., Mali P., Cheng L., Gerecht S. Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:12601-12606.
96. Yang X., Sarvestani S.K., Moeinzadeh S., He X., Jabbari E. Three-dimensional-engineered matrix to study cancer stem cells and tumorsphere formation: effect of matrix modulus. Tissue Eng. A 2013, 19:669-684.
97. Weidner N., Carroll P., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993, 143:401.
98. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 1991, 324:1-8.
99. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J. Clin. Oncol. 2006, 24:3293-3298.
100. Martínez-Corral I., Olmeda D., Diéguez-Hurtado R., Tammela T., Alitalo K., Ortega S. In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis. Proc. Natl. Acad. Sci. 2012, 109:6223-6228.
101. Vakoc B.J., Lanning R.M., Tyrrell J.A., Padera T.P., Bartlett L.A., Stylianopoulos T., Munn L.L., Tearney G.J., Fukumura D., Jain R.K. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat. Med. 2009, 15:1219-1223.
102. Bayless K.J., Kwak H.-I., Su S.-C. Investigating endothelial invasion and sprouting behavior in three-dimensional collagen matrices. Nat. Protoc. 2009, 4:1888-1898.
103. de Nigris F., Crudele V., Giovane A., Casamassimi A., Giordano A., Garban H.J., Cacciatore F., Pentimalli F., Marquez-Garban D.C., Petrillo A. CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc. Natl. Acad. Sci. 2010, 107:14484-14489.
104. Staton C.A., Reed M.W., Brown N.J. A critical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 2009, 90:195-221.
105. Kwak H.-I., Kang H., Dave J.M., Mendoza E.A., Su S.-C., Maxwell S.A., Bayless K.J. Calpain-mediated vimentin cleavage occurs upstream of MT1-MMP membrane translocation to facilitate endothelial sprout initiation. Angiogenesis 2012, 15:287-303.
106. Verbridge S.S., Chandler E.M., Fischbach C. Tissue-engineered three-dimensional tumor models to study tumor angiogenesis. Tissue Eng. A 2010, 16:2147-2152.
107. Bansal R., Tomar T., Östman A., Poelstra K., Prakash J. Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. Mol. Cancer Ther. 2012, 11:2419-2428.
108. Jain R.K., Booth M.F. What brings pericytes to tumor vessels?. J. Clin. Investig. 2003, 112:1134-1136.
109. Taeger J., Moser C., Hellerbrand C., Mycielska M.E., Glockzin G., Schlitt H.J., Geissler E.K., Stoeltzing O., Lang S.A. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol. Cancer Ther. 2011, 10:2157-2167.
110. Baker M., Robinson S.D., Lechertier T., Barber P.R., Tavora B., D'Amico G., Jones D.T., Vojnovic B., Hodivala-Dilke K. Use of the mouse aortic ring assay to study angiogenesis. Nat. Protoc. 2012, 7:89-104.
111. Chiu L.L., Montgomery M., Liang Y., Liu H., Radisic M. Perfusable branching microvessel bed for vascularization of engineered tissues. Proc. Natl. Acad. Sci. 2012, 109:E3414-E3423.
112. Chrobak K.M., Potter D.R., Tien J. Formation of perfused, functional microvascular tubes in vitro. Microvasc. Res. 2006, 71:185-196.
113. Nichol J.W., Koshy S.T., Bae H., Hwang C.M., Yamanlar S., Khademhosseini A. Cell-laden microengineered gelatin methacrylate hydrogels. Biomaterials 2010, 31:5536-5544.
114. Morgan J.P., Delnero P.F., Zheng Y., Verbridge S.S., Chen J., Craven M., Choi N.W., Diaz-Santana A., Kermani P., Hempstead B., Lopez J.A., Corso T.N., Fischbach C., Stroock A.D. Formation of microvascular networks in vitro. Nat. Protoc. 2013, 8:1820-1836.
115. Mironov V., Kasyanov V., Markwald R.R. Organ printing: from bioprinter to organ biofabrication line. Curr. Opin. Biotechnol. 2011, 22:667-673.
116. Malda J., Visser J., Melchels F.P., Jungst T., Hennink W.E., Dhert W.J., Groll J., Hutmacher D.W. 25th anniversary article: engineering hydrogels for biofabrication. Adv. Mater. 2013, 25:5011-5028.
117. Mironov V., Visconti R.P., Kasyanov V., Forgacs G., Drake C.J., Markwald R.R. Organ printing: tissue spheroids as building blocks. Biomaterials 2009, 30:2164-2174.
118. Norotte C., Marga F.S., Niklason L.E., Forgacs G. Scaffold-free vascular tissue engineering using bioprinting. Biomaterials 2009, 30:5910-5917.
119. Skardal A., Zhang J., Prestwich G.D. Bioprinting vessel-like constructs using hyaluronan hydrogels crosslinked with tetrahedral polyethylene glycol tetracrylates. Biomaterials 2010, 31:6173-6181.
120. Visconti R.P., Kasyanov V., Gentile C., Zhang J., Markwald R.R., Mironov V. Towards organ printing: engineering an intra-organ branched vascular tree. Expert. Opin. Biol. Ther. 2010, 10:409-420.
121. Miller J.S., Stevens K.R., Yang M.T., Baker B.M., Nguyen D.-H.T., Cohen D.M., Toro E., Chen A.A., Galie P.A., Yu X. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat. Mater. 2012, 11:768-774.
122. Kolesky D.B., Truby R.L., Gladman A., Busbee T.A., Homan K.A., Lewis J.A. 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Adv. Mater. 2014, 26:3124-3130.
123. Wu W., DeConinck A., Lewis J.A. Omnidirectional printing of 3D microvascular networks. Adv. Mater. 2011, 23:H178-H183.
124. Alitalo A., Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012, 31:4499-4508.
125. Hirakawa S., Detmar M., Karaman S. Lymphatics in nanophysiology. Adv. Drug Deliv. Rev. 2014, 10.1016/j.addr.2014.01.011.
126. Galler K.M., Aulisa L., Regan K.R., D'Souza R.N., Hartgerink J.D. Self-assembling multidomain peptide hydrogels: designed susceptibility to enzymatic cleavage allows enhanced cell migration and spreading. J. Am. Chem. Soc. 2010, 132:3217-3223.
127. Hartgerink J.D., Beniash E., Stupp S.I. Self-assembly and mineralization of peptide-amphiphile nanofibers. Science 2001, 294:1684-1688.
128. Hosseinkhani H., Hong P.D., Yu D.S. Self-assembled proteins and peptides for regenerative medicine. Chem. Rev. 2013, 113:4837-4861.
129. Matsusaki M., Case C.P., Akashi M. Three-dimensional cell culture technique and pathophysiology. Adv. Drug Deliv. Rev. 2014, 10.1016/j.addr.2014.01.003.
130. Ghanaati S., Webber M.J., Unger R.E., Orth C., Hulvat J.F., Kiehna S.E., Barbeck M., Rasic A., Stupp S.I., Kirkpatrick C.J. Dynamic in vivo biocompatibility of angiogenic peptide amphiphile nanofibers. Biomaterials 2009, 30:6202-6212.
131. Zhang S., Gelain F., Zhao X. Designer self-assembling peptide nanofiber scaffolds for 3D tissue cell cultures. Seminars in Cancer Biology 2005, 413-420. Elsevier.
132. Trappmann B., Chen C.S. How cells sense extracellular matrix stiffness: a material's perspective. Curr. Opin. Biotechnol. 2013, 24:948-953.
133. Stahl P.J., Romano N.H., Wirtz D., Yu S.M. PEG-based hydrogels with collagen mimetic peptide-mediated and tunable physical cross-links. Biomacromolecules 2010, 11:2336-2344.
134. da Rocha E.L., Porto L.M., Rambo C.R. Nanotechnology meets 3D in vitro models: tissue engineered tumors and cancer therapies. Mater. Sci. Eng. C Mater. Biol. Appl. 2014, 34:270-279.
135. Xu X., Sabanayagam C.R., Harrington D.A., Farach-Carson M.C., Jia X. A hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeutics. Biomaterials 2014, 35:3319-3330.
136. Charoen K.M., Fallica B., Colson Y.L., Zaman M.H., Grinstaff M.W. Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations. Biomaterials 2014, 35:2264-2271.
137. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65:71-79.
138. Taurin S., Greish K. Enhanced vascular permeability in solid tumors: a promise for anticancer nanomedicine. Tight Junctions in Cancer Metastasis 2013, 81-118. Springer.
139. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., Barry S.T., Gabizon A., Grodzinski P., Blakey D.C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013, 73:2412-2417.
140. Xiong Y.-Q., Sun H.-C., Zhang W., Zhu X.-D., Zhuang P.-Y., Zhang J.-B., Wang L., Wu W.-z., Qin L.-X., Tang Z.-Y. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res. 2009, 15:4838-4846.
141. Franses J.W., Drosu N.C., Gibson W.J., Chitalia V.C., Edelman E.R. Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis. Int. J. Cancer 2013, 133:1334-1344.
142. Apopa P.L., Qian Y., Shao R., Guo N.L., Schwegler-Berry D., Pacurari M., Porter D., Shi X., Vallyathan V., Castranova V., Flynn D.C. Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling. Part. Fibre Toxicol. 2009, 6:1.
143. Brun E., Carriere M., Mabondzo A. In vitro evidence of dysregulation of blood-brain barrier function after acute and repeated/long-term exposure to TiO(2) nanoparticles. Biomaterials 2012, 33:886-896.
144. Setyawati M.I., Tay C.Y., Chia S.L., Goh S.L., Fang W., Neo M.J., Chong H.C., Tan S.M., Loo S.C., Ng K.W., Xie J.P., Ong C.N., Tan N.S., Leong D.T. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherin. Nat. Commun. 2013, 4:1673.